21 a. Modèles ?-syn, p.23 ,
23 a. Modèles parkine, p.24 ,
30 4.5-Analyse de la fonction olfactive des rats30 b. Chez l'adulte, perception d'une odeur répulsive, p.31 ,
32 5.1-Analyse immunohistochimique, p.33 ,
35 6.1-Le locus coeruleus, ., p.36 ,
Are dopaminergic neurons selectively vulnerable to Parkinson's disease?, Advances in Neurology, vol.60, pp.148-164, 1993. ,
Parkinson's disease: pathophysiology, The Lancet, vol.337, issue.8753, pp.1321-1324, 1991. ,
DOI : 10.1016/0140-6736(91)92989-F
Deep brain stimulation in Parkinson's disease: Opposite effects of stimulation in the pallidum, Movement Disorders, vol.13, issue.6, pp.969-970, 1998. ,
DOI : 10.1002/mds.870130618
Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease, The Lancet Neurology, vol.8, issue.1, pp.67-81, 2009. ,
DOI : 10.1016/S1474-4422(08)70291-6
Animal models of Parkinson's disease, BioEssays, vol.395, issue.4, pp.308-318, 2002. ,
DOI : 10.1002/bies.10067
Neural transplantation for the treatment of Parkinson's disease, The Lancet Neurology, vol.2, issue.7, pp.437-445, 2003. ,
DOI : 10.1016/S1474-4422(03)00442-3
Animal models of Parkinson???s disease, FEBS Journal, vol.6, issue.7, pp.1156-1166, 2012. ,
DOI : 10.1111/j.1742-4658.2012.08491.x
Thalamic Stimulation for the Treatment of Tremor and Other Movement Disorders, ActaNeurochirurgica,Supplementum, vol.52, pp.109-111, 1991. ,
DOI : 10.1007/978-3-7091-9160-6_30
Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease, Progress in Neurobiology, vol.65, issue.2, pp.135-172, 2001. ,
DOI : 10.1016/S0301-0082(01)00003-X
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism, Science, vol.299, issue.5604, pp.256-259, 2003. ,
DOI : 10.1126/science.1077209
Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons, The Journal of Comparative Neurology, vol.80, issue.4, pp.479-489, 1995. ,
DOI : 10.1002/cne.903550402
Gastric alpha-synuclein immunoreactive inclusions in Meissner's and, 2006. ,
Stages in the development of Parkinson???s disease-related pathology, Cell and Tissue Research, vol.16, issue.Suppl 2, pp.121-134, 2004. ,
DOI : 10.1007/s00441-004-0956-9
Cross-talk between mitochondria and proteasome in Parkinson???s disease pathogenesis, Frontiers in Aging Neuroscience, vol.2, p.17, 2010. ,
DOI : 10.3389/fnagi.2010.00017
Techniques and basic experiments for the study of brain and behavior, Book Chapter, 1984. ,
Abrégé de neurologie, 1972. ,
Nocturnal symptom complex in PD and its management, Neurology, vol.61, issue.Issue 6, Supplement 3, pp.17-23, 2003. ,
DOI : 10.1212/WNL.61.6_suppl_3.S17
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment, The Lancet Neurology, vol.8, issue.5, pp.464-474, 2009. ,
DOI : 10.1016/S1474-4422(09)70068-7
??-Synuclein Alters Proteasome Function, Protein Synthesis, and Stationary Phase Viability, Journal of Biological Chemistry, vol.280, issue.34, pp.30009-30017, 2005. ,
DOI : 10.1074/jbc.M501308200
Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease, Neuroscience & Biobehavioral Reviews, vol.30, issue.1, pp.1-23, 2006. ,
DOI : 10.1016/j.neubiorev.2005.03.024
Parkinsonism and Dopa, Journal of Chronic Diseases, vol.22, issue.5, pp.297-301, 1969. ,
DOI : 10.1016/0021-9681(69)90072-1
New Animal Models for Parkinson's Disease, Cell, vol.101, issue.2, pp.115-118, 2000. ,
DOI : 10.1016/S0092-8674(00)80629-7
Genetic Animal Models of Parkinson's Disease, Neuron, vol.66, issue.5, pp.646-661, 2010. ,
DOI : 10.1016/j.neuron.2010.04.034
Epidemiology of Parkinson's disease, The Lancet Neurology, vol.5, issue.6, pp.525-535, 2006. ,
DOI : 10.1016/S1474-4422(06)70471-9
Voies et centres nerveux, 9ème édition, 1970. ,
Neuromelanic pigment in substantianigra neurons of rats and dogs, Neuroscience Letters, vol.3, issue.72, pp.37-42, 1986. ,
[Dyskinesia caused by L-DOPA], Revue Neurologique, vol.158, issue.1, pp.92-101, 2002. ,
Parkinson's disease and pesticide exposures, British Medical Bulletin, vol.79, issue.1, pp.219-231, 2006. ,
DOI : 10.1093/bmb/ldl018
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria, The Lancet Neurology, vol.8, issue.12, pp.1150-1157, 2009. ,
DOI : 10.1016/S1474-4422(09)70238-8
Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system, Brain Research, vol.102, issue.2, pp.201-215, 1976. ,
DOI : 10.1016/0006-8993(76)90877-5
Modulation of 6-hydroxydopamine induced alteration of the postnatal development of central noradrenaline neurons, Brain Research Bulletin, vol.9, pp.1-6, 1982. ,
Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study, Journal of Neurology, Neurosurgery & Psychiatry, vol.75, issue.12, pp.1672-1677, 2004. ,
DOI : 10.1136/jnnp.2003.028761
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system, The Journal of Neuroscience, vol.22, issue.7, pp.2780-2791, 2002. ,
Nigrostriatal ??-synucleinopathy induced by viral vector-mediated overexpression of human ??-synuclein: A new primate model of Parkinson's disease, Proceedings of the National Academy of Sciences, vol.100, issue.5, pp.2884-2889, 2003. ,
DOI : 10.1073/pnas.0536383100
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, vol.392, issue.6676, pp.605-608, 1998. ,
Neuropathological Evidence of Graft Survival and Striatal Reinnervation after the Transplantation of Fetal Mesencephalic Tissue in a Patient with Parkinson's Disease, New England Journal of Medicine, vol.332, issue.17, pp.1118-1124, 1995. ,
DOI : 10.1056/NEJM199504273321702
Fibrillization of ?-synuclein and tau in familial Parkinson's disease caused by the A53T ?-synuclein mutation, Experimental Neurology, vol.187, issue.2, pp.279-288, 2004. ,
DOI : 10.1016/j.expneurol.2004.01.007
Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease, The Lancet, vol.350, issue.9092, p.1676, 1997. ,
DOI : 10.1016/S0140-6736(05)64273-0
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson???s disease, Nature, vol.23, issue.7378, pp.547-51, 2011. ,
DOI : 10.1038/nature10648
Behavioral and Neurochemical Effects of Wild-Type and Mutated Human ??-Synuclein in Transgenic Mice, Experimental Neurology, vol.175, issue.1, pp.35-48, 2002. ,
DOI : 10.1006/exnr.2002.7882
Development of P2 olfactory glomeruli in P2-internal ribosome entry sitetau-LacZ transgenic mice, The Journal of Neuroscience, vol.19, issue.22, pp.9856-9864, 1999. ,
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms, The Lancet Neurology, vol.8, issue.12, pp.1128-1139, 2009. ,
DOI : 10.1016/S1474-4422(09)70293-5
Effects of 6-hydroxydopamine on central noradrenaline neurons during ontogeny, Brain Research, vol.99, issue.2, pp.277-291, 1975. ,
DOI : 10.1016/0006-8993(75)90029-3
Excessive bracing reactions and their control by atropine and l-DOPA in an animal analog of parkinsonism, Experimental Neurology, vol.64, issue.1, pp.33-43, 1979. ,
DOI : 10.1016/0014-4886(79)90003-7
Science, medicine, and the future: Parkinson's disease, BMJ, vol.318, issue.7179, pp.311-314, 1999. ,
DOI : 10.1136/bmj.318.7179.311
??-Synuclein Locus Triplication Causes Parkinson's Disease, Science, vol.302, issue.5646, p.841, 2003. ,
DOI : 10.1126/science.1090278
Etiology of Parkinson's disease: Genetics and environment revisited, Proceedings of the National Academy of Sciences, vol.99, issue.22, pp.13972-13974, 2002. ,
DOI : 10.1073/pnas.242594999
Pallidal and Thalamic Surgery for Parkinson's Disease, Experimental Neurology, vol.144, issue.1, pp.35-40, 1997. ,
DOI : 10.1006/exnr.1996.6385
The premotor phase of Parkinson's disease, Parkinsonism & Related Disorders, vol.13, pp.2-7, 2007. ,
DOI : 10.1016/j.parkreldis.2007.06.007
6-hydroxy-dopamine induced degeneration of central monoamine neurons, European Journal of Pharmacology, vol.5, issue.1, pp.107-110, 1968. ,
DOI : 10.1016/0014-2999(68)90164-7
6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: The turning syndrome, Pharmacology & Therapeutics. Part B: General and Systematic Pharmacology, vol.2, issue.1, pp.37-40, 1976. ,
DOI : 10.1016/0306-039X(76)90016-7
PINK1 mutations are associated with sporadic early-onset parkinsonism, Annals of Neurology, vol.56, issue.3, pp.336-341, 2004. ,
DOI : 10.1002/ana.20256
l-DOPA-Induced Dyskinesia in the Intrastriatal 6-Hydroxydopamine Model of Parkinson's Disease: Relation to Motor and Cellular Parameters of Nigrostriatal Function, Neurobiology of Disease, vol.10, issue.2, pp.165-186, 2002. ,
DOI : 10.1006/nbdi.2002.0499
Mutant ??-synuclein exacerbates age-related decrease of neurogenesis, Neurobiology of Aging, vol.29, issue.6, pp.913-925, 2008. ,
DOI : 10.1016/j.neurobiolaging.2006.12.016
Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb, Experimental Neurology, vol.197, issue.1, pp.113-121, 2006. ,
DOI : 10.1016/j.expneurol.2005.08.028
Non-motor extranigral signs and symptoms in Parkinson's disease, Parkinsonism & Related Disorders, vol.15, issue.3, pp.6-12, 2009. ,
DOI : 10.1016/S1353-8020(09)70770-9